Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China

References

• Cancer Today. Lyon: International Agency for Research on Cancer; [updated 2020 Dec; cited 2023 Mar 5]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf.
   Google Scholar
• Chen WQ, Zheng RS, Zhang SW, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71. doi:10.1016/j.canlet.2017.04.024.
   PubMed Web of Science ®Google Scholar
• Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338.
   PubMed Web of Science ®Google Scholar
• Sun DQ, Li H, Cao MM, et al. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020;17(4):879–895. doi:10.20892/j.issn.2095-3941.2020.0387.
   PubMed Web of Science ®Google Scholar
• John R, Ross H. The global economic cost of cancer. New York (NY): American Cancer Society; 2010. Report No.: 005444. Available from: www.cancer.org.
   Google Scholar
• Zhang X, Liu S, Liu Y, et al. Economic burden for lung cancer survivors in urban China. Int J Environ Res Public Health. 2017;14(3):308. doi:10.3390/ijerph14030308.
   PubMed Web of Science ®Google Scholar
• Beckles MA, Spiro SG, Colice GL, et al. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest. 2003;123(Suppl 1):97S–104S. doi:10.1378/chest.123.1_suppl.97s.
   PubMed Web of Science ®Google Scholar
• Liu CC, Shi JF, Wang H, et al. Population-level economic burden of lung cancer in China: provisional prevalence-based estimations, 2017–2030. Chin J Cancer Res. 2021;33(1):79–92. doi:10.21147/j.issn.1000-9604.2021.01.09.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Chinese guidelines for diagnosis and treatment of primary lung cancer 2018 (English version). Chin J Cancer Res. 2019;31(1):1–28.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006. doi:10.1001/jama.2014.3741.
   PubMed Web of Science ®Google Scholar
• Song ZB, Yu YF, Chen ZW, et al. Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment. Chin Med J (Engl). 2011;124(15):2279–2283.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Suda K, Wiens J, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–1024. doi:10.1016/S0140-6736(16)31473-8.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:10.1016/S0140-6736(16)30958-8.
   PubMed Web of Science ®Google Scholar
• Sun YK, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105. doi:10.1186/s13045-016-0332-8.
   PubMed Web of Science ®Google Scholar
• Arunachalam A, Li HJ, Bittoni MA, et al. Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with second-line therapies for medicare patients with advanced non-small cell lung cancer. Clin Lung Cancer. 2018;19(5):e783–e799. doi:10.1016/j.cllc.2018.05.016.
   PubMed Web of Science ®Google Scholar
• van der Welle CMC, Peters BJM, Deenen MJ, et al. Trends in drug costs and overall survival in patients with metastatic non‑small cell lung cancer in The Netherlands diagnosed from 2008 through 2014. Pharmacoecon Open. 2021;5(1):121–127. doi:10.1007/s41669-020-00220-z.
   PubMed Web of Science ®Google Scholar
• Seung SJ, Hurry M, Hassan S, et al. Cost-of-illness study for non-small-cell lung cancer using real-world data. Curr Oncol. 2019;26(2):102–107. doi:10.3747/co.26.4555.
   PubMed Web of Science ®Google Scholar
• Zhu DW, Shi XF, Nicholas S, et al. Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China. Cancer Med. 2021;10(8):2914–2923. doi:10.1002/cam4.3845.
   PubMed Web of Science ®Google Scholar
• Ding RX, Zhu DW, He P, et al. Comorbidity in lung cancer patients and its association with medical service cost and treatment choice in China. BMC Cancer. 2020;20(1):250. doi:10.1186/s12885-020-06759-8.
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jönsson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ. 2007;8(1):5–15. doi:10.1007/s10198-006-0003-8.
   PubMed Web of Science ®Google Scholar
• Cao MM, Chen WQ. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10(1):3–7. doi:10.1111/1759-7714.12916.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ma SL, Song XQ, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012;13(5):466–475. doi:10.1016/S1470-2045(12)70117-1.
   PubMed Web of Science ®Google Scholar
• Pan DJ, Wang B, Zhou XJ, et al. Clinical study on gefitinib combined with γ‑ray stereotactic body radiation therapy as the first‑line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085). Mol Clin Oncol. 2013;1(4):711–715. doi:10.3892/mco.2013.135.
   PubMedGoogle Scholar
• Venkatachalam L. The contigent valuation method: a review. Environ Impact Asses. 2004;24(1):89–124. doi:10.1016/S0195-9255(03)00138-0.
   Web of Science ®Google Scholar
• Lang HC. Willingness to pay for lung cancer treatment. Value Health. 2010;13(6):743–749. doi:10.1111/j.1524-4733.2010.00743.x.
   PubMed Web of Science ®Google Scholar
• Davis KL, Goyal RK, Able SL, et al. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer. 2015;87(2):176–185. doi:10.1016/j.lungcan.2014.11.002.
   PubMed Web of Science ®Google Scholar
• Cicin I, Oksuz E, Karadurmus N, et al. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. Health Econ Rev. 2021;11(1):22. doi:10.1186/s13561-021-00322-2.
   PubMed Web of Science ®Google Scholar
• Keusters WR, de Weger VA, Hövels A, et al. Changing costs of metastatic non small cell lung cancer in The Netherlands. Lung Cancer. 2017;114:56–61. doi:10.1016/j.lungcan.2017.10.005.
   PubMed Web of Science ®Google Scholar
• Migliorino MR, Santo A, Romano G, et al. Economic burden of patients affected by non‐small cell lung cancer (NSCLC): the LIFE study. J Cancer Res Clin Oncol. 2017;143(5):783–791. doi:10.1007/s00432-016-2326-x.
   PubMed Web of Science ®Google Scholar
• Yang SC, Lai WW, Su WC, et al. Estimating the lifelong health impact and financial burdens of different types of lung cancer. BMC Cancer. 2013;13(1):579. doi:10.1186/1471-2407-13-579.
   PubMed Web of Science ®Google Scholar
• Wang CJ, Shang M, Tong F. 山东省肺癌住院患者直接经济负担影响因素分析 [Study on the influencing factors of direct economic burden and medical insurance system of lung cancer patients in Shandong province]. Chin J Hosp Stat. 2016;23(4):254–257. In Chinese.
   Google Scholar
• Alkhatib NS, Abraham I. The six Delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2016;23(11):1209–1214.
   Google Scholar
• Alkhatib NS, McBride A, Slack M, et al. Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs). J Med Econ. 2020;23(11):1266–1272. doi:10.1080/13696998.2020.1815031.
   PubMed Web of Science ®Google Scholar
• Zarogoulidou V, Panagopoulou E, Papakosta D, et al. Estimating the direct and indirect costs of lung cancer: a prospective analysis in a Greek University Pulmonary Department. J Thorac Dis. 2015;7(Suppl 1):S12–S19.
   PubMed Web of Science ®Google Scholar
• Landi L, Cappuzzo F. Targeted therapies: front-line therapy in lung cancer with mutations in EGFR. Nat Rev Clin Oncol. 2011;8(10):571–573. doi:10.1038/nrclinonc.2011.135.
   PubMed Web of Science ®Google Scholar
• Böckerman P, ilmakunnas P. Unemployment and self-assessed health: evidence from panel data. Health Econ. 2009;18(2):161–179. doi:10.1002/hec.1361.
   PubMed Web of Science ®Google Scholar